| scholarly article | Q13442814 |
| P50 | author | Bernard Zinman | Q61337175 |
| Eleuterio Ferrannini | Q59193801 | ||
| John Buse | Q6224073 | ||
| P2093 | author name string | Mayer B Davidson | |
| Robert Sherwin | |||
| David M Nathan | |||
| Rury R Holman | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hyperglycemia | Q271993 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 173-175 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for th | |
| P478 | volume | 31 |
| Q43050598 | A new look at established therapies: practical tools for optimizing insulin use. |
| Q37750257 | A review of the response to oral antidiabetes agents in patients with type 2 diabetes |
| Q46030058 | Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. |
| Q42944964 | American Diabetes Association Postgraduate Meetings--2011. |
| Q33394779 | Anti-diabetic Agents in Type 2 Diabetes: A Review of New Data Presented and Discussed on the EASD meeting in Rome, 2008. |
| Q44818568 | Are prescribing patterns of antidiabetic medications influenced by fears of litigation? |
| Q35008794 | Bariatric surgery for type 2 diabetes: weighing the impact for obese patients |
| Q51443441 | Basal insulin glargine vs prandial insulin lispro in type 2 diabetes. |
| Q42869462 | Benefits of self‐monitoring blood glucose in the management of new‐onset Type 2 diabetes mellitus: The St Carlos Study, a prospective randomized clinic‐based interventional study with parallel groups |
| Q37834962 | Can modeling of health outcomes facilitate regulatory decision making? The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007. |
| Q37595875 | Can primary care team-based transition to insulin improve outcomes in adults with type 2 diabetes: the stepping up to insulin cluster randomized controlled trial protocol |
| Q28741419 | Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes |
| Q33610676 | Changing the treatment paradigm for type 2 diabetes |
| Q37354724 | Comparison of effect of resveratrol and vanadium on diabetes related dyslipidemia and hyperglycemia in streptozotocin induced diabetic rats |
| Q39230398 | Comparison of three weight maintenance programs on cardiovascular risk, bone and vitamins in sedentary older adults |
| Q33558371 | Comparison of thrice-daily lispro 50/50 vs thrice-daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes |
| Q30437965 | Consensus report of the coalition for clinical research-self-monitoring of blood glucose |
| Q33662676 | Could pre-diabetes be considered a clinical condition? opinions from an endocrinologist and a cardiologist |
| Q28088761 | Critical appraisal of international guidelines for the management of diabetic neuropathy: is there global agreement in the internet era? |
| Q39223235 | Diabetes in Kyrgyzstan: changes between 2002 and 2009. |
| Q34657801 | Diabetes patients' experiences with the implementation of insulin therapy and their perceptions of computer-assisted self-management systems for insulin therapy |
| Q39790288 | Different clinical prognostic factors are associated with improved glycaemic control: findings from MARCH randomized trial |
| Q35679023 | Does Device Make Any Difference? A Real-world Retrospective Study of Insulin Treatment Among Elderly Patients With Type 2 Diabetes |
| Q51345495 | Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes. |
| Q40649706 | Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan. |
| Q53322628 | Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice. |
| Q53354332 | Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. |
| Q46121472 | Expanding treatment options for type 2 diabetes: the old and the new. |
| Q36323175 | Extract of Ginkgo Biloba Ameliorates Streptozotocin-Induced Type 1 Diabetes Mellitus and High-Fat Diet-Induced Type 2 Diabetes Mellitus in Mice |
| Q42178891 | Fixed combination of repaglinide and metformin in the management of type 2 diabetes |
| Q37806134 | Glycation and biomarkers of vascular complications of diabetes |
| Q43247404 | Glycemic control in type 2 diabetic patients in public and private healthcare service |
| Q34220722 | Have we done enough with diabetic education? A pilot study |
| Q37545937 | How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid? |
| Q64985567 | Impact of structured education on glucose control and hypoglycaemia in Type-2 diabetes: a systematic review of randomized controlled trials |
| Q26776293 | Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials |
| Q37427254 | Implementing treatment guidelines for type 2 diabetes in primary care |
| Q37087031 | Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study |
| Q89769327 | Improved insulin injection technique, treatment satisfaction and glycemic control: Results from a large cohort education study |
| Q37316259 | Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. |
| Q42213836 | Inflammatory signaling: another drug target to improve glycemic control in type 2 diabetes |
| Q41860557 | Insulinization: A promising strategy for the treatment of type 2 diabetes mellitus |
| Q37325832 | Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study. |
| Q83760466 | Introduction: the best of Clinical Cornerstone |
| Q34986024 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). |
| Q37778209 | Liraglutide: A once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus |
| Q37595490 | Liraglutide: a review of its use in type 2 diabetes mellitus |
| Q37226392 | Management of new-onset diabetes mellitus after transplantation |
| Q37995863 | Managing diabetes with integrated teams: maximizing your efforts with limited time |
| Q41913272 | Metformin associated Atrial Fibrillation - A Case Report |
| Q37004040 | New combination treatments in the management of diabetes: focus on sitagliptin-metformin |
| Q37288741 | New drugs for type 2 diabetes mellitus: what is their place in therapy? |
| Q60146019 | Obesity, Metabolic Syndrome, and Diabetes: Cardiovascular Implications and Therapy |
| Q42171159 | Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes |
| Q35069677 | Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study |
| Q33982482 | Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. |
| Q39987991 | Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in type 2 diabetes. |
| Q37796716 | Preconception care for women with diabetes and prevention of major congenital malformations |
| Q46071500 | Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials |
| Q45715847 | Predictors of switching to insulin from non-insulin therapy in patients with type 2 diabetes mellitus |
| Q43044540 | Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity |
| Q33980529 | Pro's and con's of the early use of insulin in the management of type 2 diabetes: a clinical evaluation |
| Q38354830 | Prodrug delivery of novel PTP1B inhibitors to enhance insulin signalling |
| Q94464323 | Prospect of Sodium-Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes |
| Q33584386 | Protocol and baseline data from The Inala Chronic Disease Management Service evaluation study: a health services intervention study for diabetes care |
| Q34123775 | Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function |
| Q30481117 | Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes |
| Q46363801 | Rosiglitazone and pioglitazone in the treatment of diabetes mellitus |
| Q37250601 | Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study. |
| Q37857691 | Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus |
| Q57145531 | Stepping up: a nurse-led model of care for insulin initiation for people with type 2 diabetes |
| Q51362953 | Strategies for insulin initiation: insights from the French LIGHT observational study. |
| Q47781309 | Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial. |
| Q37107135 | Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis |
| Q45388469 | Synthesis and antidiabetic activity of 2,4-thiazolidindione, imidazolidinedione and 2-thioxo-imidazolidine-4-one derivatives bearing 6-methyl chromonyl pharmacophore |
| Q36849023 | The Development of INT131 as a Selective PPARgamma Modulator: Approach to a Safer Insulin Sensitizer |
| Q37267509 | The Individualized Target HbA1c: A New Method for Improving Macrovascular Risk and Glycemia Without Hypoglycemia and Weight Gain |
| Q36398223 | The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model |
| Q34113128 | The relationship between peroxisome proliferator-activated receptor-gamma and renin: a human genetics study |
| Q57413490 | The safety of rosiglitazone in the treatment of Type 2 diabetes |
| Q37844021 | Thiazolidinedione use in elderly patients with type 2 diabetes: with and without heart failure |
| Q45329033 | Thiazolidinediones and clinical outcomes in type 2 diabetes |
| Q37961238 | Treating diabetes today with gliclazide MR: a matter of numbers |
| Q37235875 | Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-b |
| Q37104865 | Type 2 diabetes mellitus: prevention of macrovascular complications. |
| Q37257467 | Use of a uniform treatment algorithm abolishes racial disparities in glycemic control |
| Q37313418 | Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. |
| Q38137389 | What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus? |
| Q45999661 | [Metformin also as first choice in patients with normal weight. Has its use increased?]. |
| Q83250012 | [Update on cardiovascular prevention and cardiac rehabilitation] |
| Q83732828 | [What is happening with the new diabetes mellitus drugs?] |
Search more.